Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- TLSA
- Price
- 1.66
- Stock movement down
- -0.06 (-4.20%)
- Company name
- Tiziana Life Sciences Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 164.68M
- Ent value
- 164.83M
- Price/Sales
- -
- Price/Book
- 17.90
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 59.71%
- 1 year return (CAGR)
- 86.14%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
TLSA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 17.90 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 120.21M |
| EPS (TTM) | -0.38 |
| FCF per share (TTM) | -0.17 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -275.00K |
| Operating income (TTM) | -31.04M |
| Net income (TTM) | -22.15M |
| EPS (TTM) | -0.38 |
| EPS (1y forward) | -0.15 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 7.25M |
| Net receivables | 4.95M |
| Total current assets | 12.72M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 16.60M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 107.00K |
| Total current liabilities | 7.40M |
| Total liabilities | 7.40M |
| Shareholder's equity | 9.20M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -9.97M |
| Capital expenditures (TTM) | 26.05K |
| Free cash flow (TTM) | -10.00M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -240.75% |
| Return on Assets | -133.45% |
| Return on Invested Capital | -237.98% |
| Cash Return on Invested Capital | -107.43% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.43 |
| Daily high | 1.43 |
| Daily low | 1.34 |
| Daily Volume | 285K |
| All-time high | 6.99 |
| 1y analyst estimate | 7.98 |
| Beta | 0.23 |
| EPS (TTM) | -0.38 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| TLSA | S&P500 | |
| Current price drop from All-time high | -76.25% | -0.89% |
| Highest price drop | -90.80% | -19.00% |
| Date of highest drop | 6 Feb 2025 | 8 Apr 2025 |
| Avg drop from high | -80.07% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 315 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
164.68M
Marketcap category
Small-cap
Description
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Employees
9
Investor relations
SEC filings
CEO
Kunwar Shailubhai
Country
USA
City
London
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page